Results 141 to 150 of about 14,564 (189)

Potential impact of nicorandil on the pharmacodynamics of anti-angiogenic agents. [PDF]

Sci Rep
Pan C, Onda K, Ebina K, Kawakami M, Yokosawa M, Hirano T, Suzuki K.   +6 more
europepmc   +1 more source

Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States. [PDF]

Pharmacoecon Open
Baljoon A, Diaby V, Suther S, Dutton M, Ali A, Eljilany I.   +5 more
europepmc   +1 more source

Efficacy and Safety of Anti-vascular Endothelial Growth Factor (VEGF) Agents in Diabetic Macular Edema. [PDF]

Cureus
Krishnan B V, Kauser N, Priya G, Sm M.
europepmc   +1 more source

Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report. [PDF]

Am J Case Rep
Sano H, Yanai R, Mitamura Y.
europepmc   +1 more source

Morphologic Changes of Macular Choroidal Neovascularization on OCT Angiography Following Faricimab Therapy in Patients With AMD. [PDF]

J Vitreoretin Dis
Loya A, Chen V, Siddiqui T, Rao P, Chang EY.   +4 more
europepmc   +1 more source

Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations. [PDF]

Biomedicines
Dascalu AM, Grigorescu CC, Ergin E, Alexandrescu C, Dumitrescu D, Nedea MI, Cristea BM, Serban D, Tribus LC, Badescu TM.   +9 more
europepmc   +1 more source

Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment. [PDF]

PLoS One
Tomemori R, Mori H, Tanaka M, Kiriishi T, Omi M, Hattori Y, Oba S, Ohnaka M, Imai H.   +8 more
europepmc   +1 more source

Real-world six-month outcomes after switching from aflibercept 2 mg to aflibercept 8 mg for neovascular age-related macular degeneration. [PDF]

Jpn J Ophthalmol
Kindo H, Hosokawa MM, Ouchi C, Matoba R, Morita T, Hayashi J, Morizane Y.   +6 more
europepmc   +1 more source

Management of diabetic macular edema: from anti-VEGF to emerging therapies. [PDF]

Front Med (Lausanne)
Ji M, Wei W, Gong H, Zhang G.
europepmc   +1 more source

Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. [PDF]

J Comp Eff Res
Shi F, Tan S, Shu Y, Liu T, Xia Y, Buehrer C, Han S.   +6 more
europepmc   +1 more source